

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Nitisinone for treating alkaptonuria ID2691

Provisional stakeholder list of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| <p><u>Company</u></p> <ul style="list-style-type: none"> • Swedish Orphan Biovitrum AB (nitisinone) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Alkaptonuria Society • Arthritis Action • Arthritis and Musculoskeletal Alliance • Find a Cure • Genetic Alliance UK • Kidney Care UK • Kidney Research UK • Metabolic Support UK • Muslim Council of Britain • National Kidney Federation • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Technologists • British Association of Urological Nurses • British Cardiovascular Society • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Renal Society • British Society of Rehabilitation Medicine • British Society for Rheumatology • National Heart and Lung Institute • Physiotherapy Pain Association • Primary Care Rheumatology Society • Renal Association • Royal College of General Practitioners • Royal College of Nursing | <p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Services Division • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Chronic Pain Policy Coalition • Circulation Foundation • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Musculoskeletal Group • Cochrane Public Health Group • Genomics England • MRC Clinical Trials Unit • Orthopaedic Research UK |

| Consultees | Commentators (no right to submit or appeal) |
|---|--|
| <ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Society of Medicine • Society for DGH Nephrologists • Society of Endocrinology • UK Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Bedfordshire CCG • NHS Calderdale CCG • The National Alkaptonuria Centre – The Royal Liverpool and Broadgreen University Hospitals NHS Trust • Welsh Government • | <ul style="list-style-type: none"> • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and social care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.